Quick Answer
Humacyte, Inc. reported Diluted EPS of $0.26 per share (loss) for fiscal year 2025.
Humacyte, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.26 | +79.4% |
| 2024 | -$1.26 | -17.8% |
| 2023 | -$1.07 | -791.7% |
| 2022 | -$0.12 | +81.8% |
| 2021 | -$0.66 | +94.3% |
| 2020 | -$11.54 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.11 | +66.7% | +54.2% |
| June 30, 2025 | -$0.24 | +50.0% | -185.7% |
| March 31, 2025 | $0.28 | +196.6% | +184.8% |
| September 30, 2024 | -$0.33 | -32.0% | +31.2% |
| June 30, 2024 | -$0.48 | -118.2% | -65.5% |
| March 31, 2024 | -$0.29 | +19.4% | -16.0% |
| September 30, 2023 | -$0.25 | +0.0% | -13.6% |
| June 30, 2023 | -$0.22 | -162.9% | +38.9% |
- Humacyte, Inc. showed an increase of +79.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Humacyte, Inc.’s diluted eps has grown by 97.7% (from $11.54 per share (loss) to $0.26 per share (loss)).
- The most recent figure is from Humacyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: